paroxetine has been researched along with Fever in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (64.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bespalov, AY; Gross, G; Mezler, M; Schoemaker, H; Sukhotina, IA; van Gaalen, MM; Wicke, K | 1 |
| Colado, MI; Izco, M; Llopis, N; O'Shea, E; Orio, L; Torres, E | 1 |
| Hetzenauer, A; Sartori, SB; Singewald, N; Whittle, N | 1 |
| Kopelman, RI; McGovern, B; Rubin, D | 1 |
| Colado, MI; Green, AR; Williams, JL | 1 |
| Johnson, MP; Nichols, DE; Schmidt, CJ; Sprague, JE | 1 |
| Cowen, PJ; Quested, DJ; Sargent, PA | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; O'Shea, E | 2 |
| Peeters, FP; Zandbergen, J | 1 |
| Kuipers, T; Vergouwen, AC | 1 |
| Bakker, A | 1 |
| Aguirre, N; Barrionuevo, M; Del Río, J; Lasheras, B; Ramírez, MJ | 1 |
| Easton, N; Fry, JR; Green, AR; Marsden, CA; O'Shea, E | 1 |
1 trial(s) available for paroxetine and Fever
| Article | Year |
|---|---|
SSRI treatment decreases prolactin and hyperthermic responses to mCPP.
Topics: Adult; Area Under Curve; Body Temperature; Cross-Over Studies; Female; Fever; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prolactin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Single-Blind Method | 1997 |
13 other study(ies) available for paroxetine and Fever
| Article | Year |
|---|---|
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Darkness; Depression; Diazepam; Fever; Fluoxetine; Light; Male; Mice; Paroxetine; Receptors, Metabotropic Glutamate; Reinforcement Schedule; Stress, Psychological; Xanthenes | 2008 |
A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.
Topics: Animals; Drug Administration Schedule; Fever; Frontal Lobe; Hypothalamus; Inflammation; Interleukin-1beta; Male; Microglia; Minocycline; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; NF-kappa B; Paroxetine; Radioligand Assay; Rats; Rats, Inbred Strains; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2010 |
Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Anxiety; Corticosterone; Corticotropin-Releasing Hormone; Dark Adaptation; Desipramine; Disease Models, Animal; Exploratory Behavior; Fever; Food Deprivation; Hypothalamo-Hypophyseal System; Magnesium; Magnesium Deficiency; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Paroxetine; Pituitary-Adrenal System; Protein Precursors; Proto-Oncogene Proteins c-fos; Radioimmunoassay; Reaction Time; RNA, Messenger; Stress, Psychological | 2012 |
Back to basics.
Topics: Adult; Antidepressive Agents, Second-Generation; Ataxia; Confusion; Drug Synergism; Fever; Headache; Herb-Drug Interactions; Hospitalization; Humans; Kava; Male; Medical History Taking; Paroxetine; Plant Extracts; Self Medication; Sleep Stages; Valerian | 2006 |
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Body Temperature Regulation; Brain; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Female; Fever; Humans; Hydroxyindoleacetic Acid; Male; Mixed Function Oxygenases; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Phenotype; Proadifen; Quinidine; Rats; Rectum; Serotonin; Serotonin Agents; Sex Factors; Tritium | 1995 |
Studies on the mechanism of p-chloroamphetamine neurotoxicity.
Topics: Animals; Brain; Clorgyline; Dopamine; Fever; Hydroxyindoleacetic Acid; Indans; Male; Monoamine Oxidase Inhibitors; N-Methyl-3,4-methylenedioxyamphetamine; Neuroprotective Agents; Neurotoxins; p-Chloroamphetamine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Serotonin Agents | 1996 |
Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR.
Topics: Animals; Body Temperature; Brain Chemistry; Chlormethiazole; Excitatory Amino Acid Antagonists; Fever; Hydroxyindoleacetic Acid; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Neuroprotective Agents; Paroxetine; Pyridines; Rats; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Serotonin | 1998 |
The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy").
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; Fever; Hippocampus; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Endings; Paroxetine; Rats; Serotonin; Time Factors; Visual Cortex | 1999 |
[Severe withdrawal symptoms with fever during paroxetine tapering off].
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Fever; Humans; Male; Paroxetine; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1999 |
[Severe withdrawal symptoms with fever upon stopping paroxetine].
Topics: Drug Administration Schedule; Fever; Humans; Paroxetine; Pulse Therapy, Drug; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1999 |
[Severe withdrawal symptoms with fever upon stopping paroxetine].
Topics: Citalopram; Drug Administration Schedule; Fever; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1999 |
Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity.
Topics: Animals; Antioxidants; Astrocytes; Binding Sites; Carrier Proteins; Fever; Frontal Lobe; Glial Fibrillary Acidic Protein; Hippocampus; Hypothermia; Male; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Neostriatum; Nerve Tissue Proteins; Neuroprotective Agents; Paroxetine; Pyramidal Cells; Rats; Rats, Wistar; Serotonin; Serotonin Plasma Membrane Transport Proteins; Thioctic Acid | 1999 |
Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia.
Topics: Animals; Brain; Brain Chemistry; Buthionine Sulfoximine; Drug Therapy, Combination; Fever; Glutathione; Hydroxyindoleacetic Acid; Liver; Male; Maleates; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Rats, Inbred Strains; Serotonin; Treatment Outcome | 2002 |